Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene

Keigo Kosaka, Norifumi Sakai, Yuya Endo, Yuga Fukuhara, Minoru Tsuda-Tsukimoto, Tatsuyuki Ohtsuka, Ichiro Kino, Tomohiko Tanimoto, Naomi Takeba, Masakatsu Takahashi, and Toshiyuki Kume

DMPK Research Laboratory, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan (K.K., Y.F., M.T.-T., T.O., I.K., T.T., N.T., M.T., T.K.); and Drug Metabolism and Analysis Department, Mitsubishi Chemical Medience Corporation, Ibaraki, Japan (N.S., Y.E.)

Received April 9, 2011; accepted May 31, 2011

ABSTRACT:

Raloxifene is extensively glucuronidated in humans, effectively reducing its oral bioavailability (2%). It was also reported to be glucuronidated in preclinical animals, but its effects on the oral bioavailability have not been fully elucidated. In the present study, raloxifene and its glucuronides in the portal and systemic blood were monitored in Gunn rats deficient in UDP-glucuronosyltransferase (UGT) 1A, Eisai hyperbilirubinemic rats (EHBRs), which hereditarily lack multidrug resistance-associated protein (MRP) 2, and wild-type rats after oral administration. The in vitro-in vivo correlation (IVIVC) of four UGT substrates (raloxifene, biochanin A, gemfibrozil, and mycophenolic acid) in rats was also evaluated. In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine. The ratio of glucuronides to unchanged drug in systemic blood was substantially higher in EHBRs (129-fold) than in the wild-type Sprague-Dawley rats (10-fold), suggesting the excretion of raloxifene glucuronides caused by MRP2. The IVIVC of the other UGT substrates in rats displayed a good relationship, but the oral clearance values of raloxifene and biochanin A, which were extensively glucuronidated by rat intestinal microsomes, were higher than the predicted clearances using rat liver microsomes, suggesting that intestinal metabolism may be a great contributor to the first-pass effect. Therefore, evaluation of intestinal and hepatic glucuronidation for new chemical entities is important to improve their pharmacokinetic profiles.

Introduction

Glucuronidation is a phase II metabolic reaction catalyzed by UDP-glucuronosyltransferase (UGT) that transforms endogenous substances and xenobiotics into more hydrophilic compounds that are subsequently eliminated through excretion of urine and/or bile. Most lipophilic drugs are initially metabolized by cytochrome P450 (P450). Therefore, during the discovery stage of new chemical entities (NCEs), pharmaceutical companies focus more on preventing the metabolism of these drugs by P450. However, over the last decade, more hydrophilic compounds have been synthesized, and new concerns regarding UGT-catalyzed metabolism have been revealed because these processes are important for detoxification and prolongation of efficacy of some drugs. UGTs are widely expressed in various tissues including the liver, kidney, and gastrointestinal tract, implying that extrahepatic metabolism may exert a critical influence on the pharmacokinetics of glucuronidated drugs. It is well known that phenolic compounds including opioid analgesics such as morphine and flavonoids are extensively glucuronidated in the liver and small intestine (Ritter, 2007). In some cases, poor oral bioavailability (F) of the drugs is attributed to the susceptibilities to glucuronidation. Therefore, extrapolation of in vitro glucuronidation data to in vivo pharmacokinetic parameters is essential but difficult because of the complex nature of UGT enzymes (Lin and Wong, 2002). Several studies on in vitro-in vivo correlation (IVIVC) for UGT substrates have been published recently (Kilford et al., 2009; Miners et al., 2010). It was reported that in vitro predictability depends on enzyme sources, experimental conditions, and the occurrence of atypical glucuronidation kinetics, and thus selection of an appropriate approach is a key point to predict pharmacokinetics successfully.

F of raloxifene, a selective estrogen receptor modulator used in the treatment of osteoporosis, in humans has been reported as only 2% (Eli Lilly clinical data, Indianapolis, IN; Mizuma, 2009). UGT1A8 and UGT1A10, isozymes that are absent in the human liver, are thought to glucuronidate raloxifene mainly in the intestine and lead to extremely low F (Kemp et al., 2002; Jeong et al., 2005). F of raloxifene in rats and dogs was originally reported as 39 and 17%, respec-
Reagents. Raloxifene, β-glucuronidase (type IX-A, from Escherichia coli), glucose 6-phosphate, and NADP were purchased from Sigma-Aldrich (St. Louis, MO). Mycophenolic acid, biochanin A, gemfibrozil, and EDTA were purchased from BD Gentest (Woburn, MA). Liver and intestinal microsomes from SD rats, beagle dogs, and humans were obtained from XenoTech, LLC (Lenexa, KS). All chemicals were analytical grade or the highest quality available.

Animals. All animal procedures were conducted under protocols approved by the Mitsubishi Tanabe Institutional Animal Care and Use Committee. Eight-week-old male Wistar rats, SD rats, Gunn rats, and EHBRs were obtained from Japan SLC (Shizuoka, Japan). Male SD rats (9–10 weeks old) with catheters implanted in the portal and jugular vein were obtained from Charles River Japan (Yokohama, Japan). Rats were kept in a temperature- and humidity-controlled environment and were allowed to acclimate for 1 week before use. Male beagle dogs (7–17 months old) were obtained from Kitayama Labs (Nagano, Japan). Male cynomolgus monkeys (42–61 months old) were obtained from Nafouvanny (Dong Nai, Vietnam). These animals were housed in Mitsubishi Chemical Medience facilities where the temperature and humidity were controlled.

Preparation of Microsomes. To compare the metabolic activities of different strains of rats, liver and intestinal microsomes from SD rats, EHBRs, Wistar rats, and Gunn rats were prepared (pooled, n = 3). Rat liver microsomes were prepared using standard techniques (von Molike et al., 1993). In brief, pooled microsomes from three individuals were prepared by ultracentrifugation (11,000g for 20 min and 104,700g for 1 h twice). Microsomal pellets were resuspended in 0.1 M phosphate-buffered saline (PBS) (pH 7.4) containing 20% glycerol. The total protein concentration was determined using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) using bovine serum albumin (BSA) as a standard. The prepared microsomes were stored at −80°C until use. Rat intestinal microsomes were prepared as described in a previous study by another group (Perloff et al., 2004). In brief, after exsanguination, 15-cm sections of the upper intestines from the duodenum to the jejunum were immediately isolated, and the intestinal segments were flushed and incubated in solution A (pH 7.3) containing 1.5 mM KCl, 96 mM NaCl, 27 mM sodium citrate, 9.6 mM PBS, and protease inhibitor (20 tablets/l) with bubbling oxygen for 15 min at 4°C. The intestinal segments were filled with solution B (pH 7.0) containing 1.5 mM KCl, 96 mM NaCl, 1.5 mM EDTA, 1 mM dithiothreitol, 0.1% BSA, 9.6 mM PBS, and protease inhibitor (20 tablets/l). After tapping the intestinal segments on an ice-cooled plate for 2 min to peel the epithelial cells off the intestinal wall, the suspension in the lumen was collected. The suspension was centrifuged at 800g for 10 min, and the resulting pellets were resuspended in solution C (pH 7.0) containing 5 mM histidine, 0.25 M sucrose, 0.5 mM EDTA, and protease inhibitor (20 tablets/l). The cell pellets were washed with solution C and homogenized and centrifuged at 15,000g for 10 min. The supernatant was collected, and 5 volumes of 52 mM CaCl₂ were added. The tubes containing microsomes were gently mixed, allowed to stand for 15 min, and centrifuged at 2000g for 10 min. The resulting microsomal pellets were suspended in solution D (pH 7.4) containing 20% glycerol, 10 mM EDTA, and 0.1 M Tris-HCl buffer. The total protein concentration was determined by the BCA protein assay, and the microsomes were stored at −80°C until use.

Microsomal Incubation. CLint was determined using the substrate depletion method (n = 3–5). Substrate solutions were prepared at a final concentration of 2 μM in dimethyl sulfoxide and acetonitrile (0.01 and 0.99% final concentrations, respectively) except for gemfibrozil (10 μM final concentration). The substrates were incubated in 96-well plates and placed on a heating block at 37°C. The suspensions containing microsomes (0.5 mg/ml protein except for biochanin A, 0.1 mg/ml protein) were either dispensed into the 50 mM Tris-HCl solution (pH 7.5) with 25 μg/ml amelicanin and 8 mM MgCl₂ for UGT reactions or into the 72.5 mM PBS with 5 mM MgCl₂ and 1 mM EDTA for P450 reactions as final concentrations. The suspensions were vortexed and allowed to stand for 10 min in the heating block, and the metabolism assay was initiated by addition of 2 mM UDPGA or the NADPH-generating system containing 1 mM NADP, 10 mM glucose 6-phosphate, and 2 units/ml glucose-6-phosphate dehydrogenase as final concentrations. All assays were incubated for a maximum of 60 min, and reactions were terminated with 4 volumes of acetonitrile containing 0.1% formic acid and verapamil as the internal standard (IS). The samples were then centrifuged, and the supernatant was filtered and transferred to the other 96-well plates for analysis using a liquid chromatography/tandem mass spectrometry (LC-MS/MS) system as described below.

Microsomal Binding. The unbound fraction in rat liver microsomal suspensions (fu, mic) was determined in triplicate by ultracentrifugation. The microsomes were suspended in 72.5 mM PBS at the same concentration as that used for metabolic stability experiments. The samples for binding studies were centrifuged at 436,000g for 4 h at 37°C, and aliquots of the centrifuged upper fraction were transferred into 15 volumes of acetonitrile containing IS. Standard samples containing the same matrices were prepared, and the unbound compound concentrations in the incubation mixtures were quantified using LC-MS/MS.

Plasma Protein Binding. The unbound fraction in rat plasma (fu, p) was determined in triplicate by equilibrium dialysis using a serum binding system (BD Gentest). Plasma samples were spiked with the test compound (10 μM final concentration), and the device containing plasma and PBS was reciprocated in a CO₂ incubator at 37°C for 20 h. The resulting PBS samples were transferred into 8 volumes of acetonitrile containing IS. Standard samples containing the same matrices were prepared, and the unbound compound concentration in the plasma was quantified using LC-MS/MS.

Blood/Plasma Concentration Ratio. The blood/plasma concentration ratio (Rb) was determined in vitro after incubation of the compounds with fresh rat blood in duplicate. Blood was warmed to 37°C, and the test compound was
spiked at a 10 µM final concentration. The blood samples were incubated at 37°C for 5 min and divided into two portions. After centrifugation of the aliquots, the plasma and blood samples were transferred into 4 volumes of acetonitrile containing IS, centrifuged, and filtered. Standard samples containing the same matrices were prepared, and the compound concentration in plasma and blood was quantified by LC-MS/MS.

Pharmacokinetic Studies in Animals. Raloxifene (1 mg/kg b.wt.) was dissolved in a solution containing ethanol, polyethylene glycol 300, and water (1:4.5) as reported previously (Lindström et al., 1984) and administered intravenously at a volume of 0.5 ml/kg to fasted SD rats, Wistar rats, EHBRS, and Gunn rats (n = 3). Blood samples were collected from the animals at 0.05, 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. The plasma samples were separated by centrifugation and stored at −20°C. The plasma samples were processed for analysis by protein precipitation with acetonitrile containing IS, followed by centrifugation and filtration. Standard samples containing the same matrices were prepared, and the compound concentrations in the plasma were quantified using LC-MS/MS. For monitoring drug concentrations in portal and systemic plasma after 3–4), and blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. For monitoring drug concentrations in portal and systemic plasma after oral administration to EHBRS, Wistar rats, and Gunn rats, all animals were sacrificed at five or six time points (n = 3), and blood samples were collected. Intravenous (n = 2) or oral (n = 3) administration of raloxifene to beagle dogs was conducted using the same solution as that administered to the rats, and pharmacokinetic profile studies in cynomolgus monkeys were performed in the same manner (n = 2). When raloxifene was studied in dogs, pharmacokinetic parameters before and after cannulation in the portal vein were compared. The other UGT substrates, biochanin A (50 mg/kg p.o.), mycophenolic acid (10 mg/kg p.o.), and gemfibrozil (30 mg/kg p.o.), were administered to intact SD rats (intravenous) or cannulated SD rats (oral) under the same conditions used for raloxifene (n = 3). The preparation of plasma samples was as described above except for gemfibrozil, for which the collected plasma samples were immediately transferred to acetonitrile (containing 0.1% formic acid) and IS to avoid degradation of its acyl glucuronide.

Quantification of Glucuronides. The glucuronide concentrations of raloxifene and biochanin A were estimated through a hydrolysis assay using β-glucuronidase. The samples were incubated in the presence of 250 units of β-glucuronidase at 37°C for 12 to 15 h, and the completion of hydrolysis was ascertained by LC-MS/MS analysis. The glucuronide concentration of gemfibrozil was determined UV detection without a hydrolysis assay, in which it was assumed that the UV absorbances of the unchanged drug and glucuronide were the same. Because only traces of mycophenolic acid glucuronides were detected by UV, these were not quantified.

LC-MS/MS Analysis. Qualitative analysis for the identification of metabolites was performed using an HP1000 system (Agilent Technologies, Santa Clara, CA) equipped with a triple quadrupole Quattro Micro mass spectrometer (Waters, Milford, MA). LC conditions were as follows: column temperature, 40°C; column, CAPCELL PAK MGH II (2.0 mm i.d. × 150 mm, 3 µm; Shiseido, Tokyo, Japan); gradient elution at 0.2 ml/min, with acetonitrile and 10 mM ammonium acetate: UV detection, 290 nm; and run time, 20 min. The main working parameters for mass spectrometers were as follows: ion mode, electrospray ionization, positive and negative; capillary voltage, 3 kV; cone voltages, 20 and 40 V; source temperature, 100°C; and desolvation temperature, 350°C. The quantitative analysis for unchanged compounds was performed using an Acuity UPLC system equipped with a triple quadrupole mass spectrometer (Xevo TQ MS; Waters). UPLC conditions were set as follows: column temperature, 50°C; column, Waters Acuity UPLC BEH C18 (2.1 mm i.d. × 30 mm, 1.7 µm); gradient elution at 0.5 µl/min, with acetonitrile and 10 mM ammonium acetate; and run time, 3 min. The parameters for mass spectrometers were as follows: ion mode, electrospray ionization, positive for raloxifene, biochanin A, and mycophenolic acid and negative for gemfibrozil; multireaction monitoring method with transitions of m/z 474 → 112 for raloxifene, m/z 285 → 213 for biochanin A, m/z 321 → 159 for mycophenolic acid, and m/z 249 → 121 for gemfibrozil; capillary voltage, 0.5 kV; cone voltage and collision energy, 50 V and 30 eV for raloxifene, 50 V and 40 eV for biochanin A, 40 V and 35 eV for mycophenolic acid, and 20 V and 30 eV for gemfibrozil; source temperature, 150°C; and desolvation temperature, 600°C.

Estimation of Fh, Fa · Fg, and F. Fh was calculated by dividing the systemic plasma AUCs (AUCsys) by the portal plasma AUCs (AUCpv) after oral administration to animals. Fa · Fg was estimated using eq. 1:

\[ Fa \cdot Fg = \frac{Qpv \cdot Rb}{(AUCpv - AUCsys) \cdot dose} \] (1)

where Qpv is the blood flow in the portal vein, which was assumed to be 70% of the hepatic blood flow (Qh) set at 55 ml·min⁻¹·kg⁻¹·b.wt. for rats or 31 ml·min⁻¹·kg⁻¹·b.wt. for dogs (Davies and Morris, 1993). F was calculated by multiplying Fh and Fa · Fg when AUCpv was available. If AUCpv was not available, F was calculated by dividing the oral AUC by the intravenous AUC normalized with dose.

IVIVE of UGT Substrates in Rats. Data from incubations with either P450 or UGT cofactors were analyzed using a nonlinear single exponential fit, and the CLint values (milliliters per minute per milligram of protein) were calculated from the elimination rate constant k̄, volume of incubation, and amount of microsomal protein in incubation. CLint values obtained were corrected for experimentally determined fu, mic to give CLint, u, and were scaled to the whole-body clearance, CLint, w (milliliters per minute per kilogram body weight) for rats using eq. 2:

\[ \frac{\text{CL}_{\text{int}, w}}{\text{CL}_{\text{int}, u}} = k \cdot 50 \text{ mg microsomes/g liver} \cdot 37.8 \text{ g liver/kg b.wt.} \] (2)

where 50 mg of microsomes/g liver was a scaling factor (Iwatsubo et al., 1996; Zhou et al., 2002) and 37.8 g liver/kg b.wt. was the liver weight used (Luttringer et al., 2003).

The observed hepatic clearance values after intravenous administration were converted to CLint, v values using the well stirred or parallel tube liver models, defined in eqs. 3 and 4, respectively:

- Observed CLint, v = CLint, u/p · Rb/(1 − CLint/v/Qh) (3)
- Observed CLint, v = −Qh/fu·p · Rb · ln(1 − CLint/v/Qh) (4)

where CLv is the hepatic blood clearance. For biochanin A, the calculated CLv value exceeded the Qh and, therefore, CLv was assumed to be 90% of the hepatic blood flow as reported previously by another group (Cubit et al., 2009). The renal clearance of the four compounds used in this study was minor; therefore, hepatic clearance was assumed to be equal to the total clearance. The observed CLint, p.o. was calculated from the oral plasma clearance using eq. 5, which assumed complete absorption and no intestinal metabolism:

\[ \text{Observed} \text{ CL}_{\text{int}, p.o.} = \text{ CL}_{\text{int}, u}/\text{ fu} \cdot \text{ p} \cdot \text{ Rb} \] (5)

Results

In Vitro Hepatic and Intestinal Intrinsic Clearance of Raloxifene. The in vitro CLint, v values of raloxifene were estimated using liver and intestinal microsomes (XenoTech, LLC) fortified with NADPH or UDPGA. The final values were corrected with the free fraction in microsomal incubation (fu, mic, 0.278) (Table 1). The in

![Table 1](https://doi.org/10.1093/dmd/474.112)

**Table 1.** CLint, v of raloxifene metabolism by rat, dog, monkey, and human liver and intestinal microsomes. Microsomal incubations were fortified with UDPGA or NADPH. CLint, u values represent the mean ± S.D. of three determinations.
vitro CL_{int,u} values for glucuronidation determined with intestinal microsomes were higher than those with liver microsomes among the tested species, and the values using human intestinal microsomes were the highest. In contrast, the in vitro CL_{int,u} values for P450-catalyzed metabolism were higher with liver microsomes than with intestinal microsomes for these species.

The liver and intestinal microsomes were prepared from SD rats, Wistar rats, EHBRs, and Gunn rats, and the in vitro CL_{int,u} values of raloxifene were compared. As expected, the in vitro CL_{int,u} for glucuronidation determined with Gunn rat microsomes was significantly lower than that with Wistar rat microsomes (Fig. 1A). The in vitro CL_{int,u} values for P450 metabolism in EHBRs and Gunn rats were lower than those in SD and Wistar rats, respectively (Fig. 1B).

**Pharmacokinetics of Raloxifene.** LC-MS/MS analysis with UV detection (290 nm) of the SD rat portal plasma samples at 15 min after oral administration of raloxifene resulted in the appearance of two glucuronide peaks as major metabolites (Fig. 2). Other metabolites such as sulfated or oxidized raloxifene were less. After incubation of this plasma sample in the presence of β-glucuronidase, the two major peaks disappeared. The plasma concentration versus time curves of raloxifene and its glucuronides in SD rats showed rapid absorption and extensive glucuronidation (Fig. 3A). Fa, Fg, and Fh in SD rats were estimated to be 0.16 and 0.33, respectively, and the AUC ratio of glucuronides to the unchanged drug was 5.73 and 9.67 in the portal and systemic plasma, respectively (Table 2). The pharmacokinetics in Gunn and wild-type Wistar rats exhibited significant differences (Fig. 3, B and D). Fa, Fg, and Fh in Gunn rats were 0.63 and 0.43, respectively; these values were twice those observed (0.34 and 0.20, respectively) in Wistar rats. The AUC ratio of glucuronides to unchanged drug in the portal plasma was 2.51 in Wistar rats and 0.03 in Gunn rats. The plasma concentration of raloxifene glucuronides in EHBRs was dramatically higher than that in wild-type SD rats (Fig. 3, A and C). The AUC ratio of glucuronides to unchanged drug in EHBRs was 46.8 in the portal plasma and 129 in the systemic plasma (Table 2).

The PK parameters of raloxifene in beagle dogs were examined before and after implantation of catheters in the portal vein. The total clearance and F were similar before and after the cannulation. Fa, Fg, and Fh in dogs were estimated to be 0.36 and 0.16, respectively (Fig. 3E; Table 2). F in dogs (0.044 and 0.052) was comparable to F in SD rats (0.048), but the AUC ratios of glucuronides to unchanged drug were lower in dogs (portal, 0.27; systemic, 1.34) than in rats (portal, 5.73; systemic, 9.67). F in cynomolgus monkeys was also comparable (0.030) with those in rats and dogs, but the AUC ratios of glucuronides to unchanged drug in systemic plasma were higher in monkeys (85.0) than in rats and dogs (Fig. 3F; Table 2).

**IVIVC of Other UGT Substrates in Rats.** The in vitro CL_{int,u} values of biochanin A, mycophenolic acid, and gemfibrozil were determined using rat liver and intestinal microsomes (Table 3). The CL_{int,u} values of biochanin A for glucuronidation were extremely high in both rat liver and intestinal microsomes. The CL_{int,u} values of mycophenolic acid for glucuronidation were higher in rat intestinal microsomes than in rat liver microsomes. In contrast, CL_{int,u} values of gemfibrozil for glucuronidation were lower in rat intestinal microsomes than in rat liver microsomes. In all cases, the in vitro CL_{int,u} values for glucuronidation determined with intestinal microsomes were higher than those with liver microsomes among the tested species, and the values using human intestinal microsomes were the highest. In contrast, the in vitro CL_{int,u} values for P450-catalyzed metabolism were higher with liver microsomes than with intestinal microsomes for these species.
values for P450 metabolism were less than those for glucuronidation. The in vitro hepatic CLint,u values for glucuronidation were scaled to whole-body clearance values (milligrams per minute per kilogram b.wt.) and were compared with the in vivo CLint values obtained from both intravenous and oral pharmacokinetic data (Fig. 4). For calculation of the in vivo CLint values, the following Rh, plasma protein binding, and fu, mic values were incorporated. The Rb values for gemfibrozil, mycophenolic acid, raloxifene, and biochanin A were 0.56, 0.63, 1.07, and 0.75, respectively. The plasma protein binding values for these compounds were 98.9, 99.2, 99.4, and 98.8%, respectively. The fu, mic values for these compounds were 0.907, 0.776, 0.278, and 0.600, respectively. The IVIVC from intravenous clearance values was relatively good, but the CLint,h values of raloxifene and biochanin A obtained from the oral pharmacokinetic data were significantly underestimated, supporting the contribution of intestinal metabolism to a first-pass effect. Fa · Fg and Fh of biochanin A, mycophenolic acid, and gemfibrozil were examined after oral administration to SD rats (Table 4). Biochanin A, which is susceptible to extremely high glucuronidation, exhibited low Fa · Fg (0.15), whereas gemfibrozil and mycophenolic acid, compounds with relatively low CLint for glucuronidation, demonstrated high Fa · Fg (1.40 and 1.17, respectively).

Discussion

Conjugation reactions have been increasingly recognized as important metabolic processes that play a strong role in the pharmacokinetics of some drugs; therefore, prediction of the clearance of such drugs is necessary. However, unlike that for P450 substrates, the IVIVC for UGT substrates has not been studied adequately because the amount of UGTs expressed in tissues is uncertain, and the intraluminal localization of the catalytic sites, which require activation for in vitro glucuronidation, makes IVIVC more complex (Lin and Wong, 2002). UGTs are widely expressed in various tissues including the liver, kidney, and gastrointestinal tract (Ohno and Nakajin, 2009), and the importance of extrahaepatic glucuronidation has been reported (Ritter et al., 2007). Flavonoids (polyphenolic phytochemicals) were used as model UGT substrates in several studies in which not only hepatic but also intestinal glucuronidation and subsequent excretion by efflux transporters were reported (Jia et al., 2004; Zhang et al., 2007).

Raloxifene also has phenolic groups, and its oral bioavailability in humans is very low because of a high glucuronidation rate catalyzed by UGT1A8 and 1A10 in the intestine (Kemp et al., 2002; Jeong et al., 2005; Mizuma, 2009); its conjugates are subsequently excreted into the gut lumen by P-glycoprotein and/or MRPs. These enzyme and transporter couplings are thought to result in long half-lives because of enteric recycling despite the extensively high oral clearance (Jeong et al., 2004; Xu et al., 2009).

In the present study, species differences in CLint,u for in vitro glucuronidation of raloxifene were investigated (Table 1), and the results were compared with its pharmacokinetics (Table 2). To activate UGT, alamethicin was used as a pore-forming agent according to previous reports (Dalvie et al., 2008; Cubitt et al., 2009). The results were consistent with those reported by others, for which the gluc-

TABLE 2
Pharmacokinetic parameters of raloxifene after intravenous or oral administration to SD rats, EHBRs, Wistar rats, Gunn rats, beagle dogs, and cynomolgus monkeys

<table>
<thead>
<tr>
<th>Animals</th>
<th>1 mg/kg i.v.</th>
<th>2 mg/kg p.o.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CLint</td>
<td>Vdss</td>
</tr>
<tr>
<td></td>
<td>ml/h kg⁻¹</td>
<td>ml/kg</td>
</tr>
<tr>
<td>SD rats</td>
<td>2051 (172)</td>
<td>3240 (440)</td>
</tr>
<tr>
<td>EHBRs</td>
<td>1323 (153)</td>
<td>3673 (499)</td>
</tr>
<tr>
<td>Wistar rats</td>
<td>1475 (323)</td>
<td>4015 (1673)</td>
</tr>
<tr>
<td>Gunn rats</td>
<td>1305 (158)</td>
<td>4967 (595)</td>
</tr>
<tr>
<td>Dogs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intact</td>
<td>1057</td>
<td>3157</td>
</tr>
<tr>
<td>Cannulated</td>
<td>1163</td>
<td>3022</td>
</tr>
<tr>
<td>Monkeys</td>
<td>909</td>
<td>3847</td>
</tr>
</tbody>
</table>

N.D., not determined.
The CLint, u values obtained with dog liver or intestinal microsomes for glucuronidation than for P450 metabolism in intestinal microsomes. H11006

The mean that all the CLint, u values among investigated animals were higher for than those with rat or human liver microsomes. Our study also showed that the mean CLint, u values with rat or human intestinal microsomes were higher than those with rat or human liver microsomes. Comparing these in vitro CLint, u values with the Fa · Fg and Fh values in the two animals demonstrated a reasonable relationship. In humans and monkeys, the raloxifene concentrations in portal plasma were not available; therefore, Fa · Fg was calculated from intravenous and oral pharmacokinetic data (total clearance in human = 0.647 l · h⁻¹ · kg⁻¹; Eli Lilly clinical data) by assuming Fh = 1 − CLb/Qh and Fa · Fg = F/Fh. When Qh values in humans and monkeys were set at 20.7 and 43.6 ml · min⁻¹ · kg⁻¹ (Davies and Morris, 1993), the calculated Fa · Fg values were 0.045 and 0.041, respectively. The Fa of raloxifene in humans was reported as 0.63 (Eli Lilly clinical data), and its permeability was high in our in-house study using Caco-2 cells (data not shown). Therefore, intestinal glucuronidation must be a main factor contributing to the first-pass effect.

In the present study using Gunn and Wistar rats, glucuronidation of raloxifene by UGT1As was suggested (Fig. 3, B and D; Table 2). The Fa · Fg and Fh values in Gunn rats were 2-fold higher than those in Wistar rats, respectively, indicating that raloxifene was glucuronidated in the intestine as well as in the liver. In the comparison of EHBRs with SD rats (Fig. 3, A and C), the differences in Fa · Fg and Fh were small, and the ratio of glucuronides to unchanged drug in systemic plasma was much higher in EHBRs, suggesting that the excretion of raloxifene glucuronides was influenced by MRP2. Some groups have reported a compensatory up-regulation of enzymes and transporters in Gunn and MRP2-deficient TR rats (Kim et al., 2003; Wang et al., 2009). Flavonoids such as apigenin are efficiently metabolized by Gunn rats because of compensatory up-regulation of intestinal UGT 2Bs and hepatic efflux transporters, which increases their disposition and limits their oral bioavailabilities. In our studies, CLint, u values for P450 metabolism determined with liver microsomes from Gunn rats and EHBRs were lower than those from Wistar and SD rats (Fig. 2); therefore, P450s responsible for the oxidation of raloxifene did not show compensatory up-regulation. CLint, u values for glucuronidation determined with microsomes from Gunn rats were lower than those from Wistar rats; implying that UGTs responsible for glucuronidation of raloxifene were not up-regulated. Of interest, species differences in the ratio of glucuronides to unchanged drugs were observed despite comparable CLint, u values for glucuronidation in dogs, rats, and monkeys. These ratios in the systemic plasma in dogs, SD rats, and monkeys were 1.34 to 1.84, 9.67, and 85.0, respectively, and the ratio in humans was reported as 70 to 90 (Eli Lilly clinical data). The ratios in monkeys and humans were closer to those in EHBRs than to those in wild-type SD rats, indicating that excretion of raloxifene glucuronides into the intestinal lumen and bile may significantly differ among these species. Expression of MRP2 in rat, dog, and human intestine has been reported (Mottino et al., 2000; Conrad et al., 2001), but species differences in transport activity of raloxifene glucuronides have not been reported. A schematic representation of the intestinal and hepatic disposition of raloxifene is presented in Fig. 5. Further studies are needed to understand the differences in raloxifene glucuronide levels in circulation after administration in these species.

The in vitro hepatic CLint, u values of raloxifene, biochanin A, mycophenolic acid, and gemfibrozil (Table 3) for glucuronidation were scaled to whole-body clearances (milligrams per minute per kilogram body weight) and compared with their observed in vivo CLint, u values (Fig. 4; Table 4). These compounds have been reported to be mainly excreted in bile as glucuronides in rats (Curtis et al., 1985; Jia et al., 2004; Takekuma et al., 2007). Therefore,
TABLE 4

Pharmacokinetic parameters of gemfibrozil, mycophenolic acid, raloxifene, and biochanin A after intravenous or oral administration to SD rats

| Compounds          | Dose (mg/kg) | CL tot (ml/min/kg) | Vdss (ml/kg) | AUC Portal (ng·h/ml) | AUC Systemic (ng·h/ml) | Fa | Fg | F
|--------------------|--------------|--------------------|--------------|---------------------|------------------------|----|----|----
| Gemfibrozil        | 1            | 437 (154)          | 2234 (1397)  | 7626 (3244)         | 30                     | 44,583 (31,358)  | 62,320 (20,397) | 0.17 (0.03) | 0.18 (0.01) | 0.65 (0.16) | 1.40 (0.64) | 0.85 (0.19) |
| Mycophenolic acid  | 3            | 107 (49)           | 637 (265)    | 34,366 (20,858)     | 10                     | 46,901 (2900)    | 135,027 (23,271) | N.D. | N.D. | 0.94 | 1.17 | 1.10 |
| Raloxifene         | 1            | 2051 (172)         | 3260 (480)   | 553 (152)           | 2                     | 11,4 (0.7)       | 59.3 (11.4)      | 9.67 (4.65) | 0.16 (0.06) | 0.33 (0.11) | 5.73 (1.14) | 9.67 (4.65) |
| Biochanin A        | N.D. not determined |                  |              |                     |                        |                |              |                     | 0.016 (0.008) | 0.15 (0.06) | 0.0024 (0.0012) |

Values in parentheses represent S.D.s. For mycophenolic acid, the S.D. was not calculated because the difference between systemic and portal AUCs was too small; therefore, Fa · Fg was estimated from each averaged AUC.

N.D.: not determined.

In conclusion, the impact of intestinal glucuronidation on the pharmacokinetics of UGT substrates was investigated by in vitro and in vivo methods. The contribution of intestinal and hepatic glucuronidation of raloxifene to first-pass effect was demonstrated in rats and dogs. The pharmacokinetic studies in EHBRS indicated the excretion of raloxifene glucuronides by MRP2, which is possibly different among animals. The in vitro intestinal CLint values of gemfibrozil were successfully predicted using rat liver microsomes in the absence of BSA. Rat UGT isoforms responsible for glucuronidating gemfibrozil and their selectivity of substrates have not been fully elucidated; therefore, further studies are needed. In several studies, models for Fg prediction of drugs, particularly for CYP3A substrates, which are metabolized in the small intestine, have been proposed (Galetin and Houston, 2006; Yang et al., 2007; Gertz et al., 2010; Kadono et al., 2010). These approaches have not been applied extensively to UGT substrates, which are eliminated through species- and/or tissue-dependent glucuronidation. In most pharmaceutical companies, NCEs not susceptible to P450-catalyzed metabolism have been eagerly investigated and synthesized by introducing hydrophilic groups into their structures. Therefore, prediction of Fg for such compounds, which are often eliminated through phase II metabolism and subsequent excretion, is becoming essential. For anionic compounds, the interactions of conjugating enzymes with transporters have been increasingly recognized as an important process of elimination (Nies et al., 2008; Pang et al., 2009; Sun et al., 2010). Therefore, comprehensive studies including metabolism and transport are required.

In conclusion, the impact of intestinal glucuronidation on the pharmacokinetics of UGT substrates was investigated by in vitro and in vivo methods. The contribution of intestinal and hepatic glucuronidation of raloxifene to first-pass effect was demonstrated in rats and dogs. The pharmacokinetic studies in EHBRS indicated the excretion of raloxifene glucuronides by MRP2, which is possibly different among animals. The in vitro intestinal CLint, h values could be predicted quite well from the in vitro hepatic CLint, u values for glucuronidation except for raloxifene. The CLint, u value of raloxifene with rat liver microsomes in the presence of NADPH was comparable to that in the presence of UDPGA; this underestimation may be caused by the exploration that did not incorporate P450-catalyzed metabolism into hepatic clearance. The oral clearance values for raloxifene and biochanin A were much higher than the predicted values, implying that intestinal glucuronidation was a great contributor. The in vitro intestinal CLint, u values for glucuronidation relatively corresponded to the Fa · Fg values for the four compounds investigated. Biochanin A is also a human UGT1A10 substrate, which is considered to be an important isoform in the gastrointestinal tract (Lewinsky et al., 2005). With regard to this compound, much less is known about the intestinal effect on presystemic elimination in humans and the responsible UGT isoforms in rats. There are several publications on IVIVC for UGT substrates (Kilford et al., 2009; Miners et al., 2010). It is well known that in vitro predictability of CLint depends on enzyme sources, experimental conditions, and the occurrence of atypical glucuronidation kinetics. In some cases, in vitro CLint values using microsomes were underestimated in comparison with in vivo values. It was reported that addition of BSA to the incubation improved the predictability from microsomal data, in particular for UGT2B7 substrates (Rowland et al., 2007, 2008). However, Kilford et al. (2009) reported that the human CLint value of gemfibrozil, a UGT 2B7 substrate, was overestimated 10-fold when BSA was added to the microsomal incubation. In the present study, the rat CLint value of gemfibrozil was successfully predicted using rat liver microsomes in the absence of BSA. Rat UGT isoforms responsible for glucuronidating gemfibrozil and their selectivity of substrates have not been fully elucidated; therefore, further studies are needed. In several studies, models for Fg prediction of drugs, particularly for CYP3A substrates, which are metabolized in the small intestine, have been proposed (Galetin and Houston, 2006; Yang et al., 2007; Gertz et al., 2010; Kadono et al., 2010). These approaches have not been applied extensively to UGT substrates, which are eliminated through species- and/or tissue-dependent glucuronidation. In most pharmaceutical companies, NCEs not susceptible to P450-catalyzed metabolism have been eagerly investigated and synthesized by introducing hydrophilic groups into their structures. Therefore, prediction of Fg for such compounds, which are often eliminated through phase II metabolism and subsequent excretion, is becoming essential. For anionic compounds, the interactions of conjugating enzymes with transporters have been increasingly recognized as an important process of elimination (Nies et al., 2008; Pang et al., 2009; Sun et al., 2010). Therefore, comprehensive studies including metabolism and transport are required.

In conclusion, the impact of intestinal glucuronidation on the pharmacokinetics of UGT substrates was investigated by in vitro and in vivo methods. The contribution of intestinal and hepatic glucuronidation of raloxifene to first-pass effect was demonstrated in rats and dogs. The pharmacokinetic studies in EHBRS indicated the excretion of raloxifene glucuronides by MRP2, which is possibly different among animals. The in vitro intestinal CLint, h corresponds with Fa · Fg for UGT substrates examined in rats. Therefore, evaluation of intestinal and hepatic glucuronidation for NCEs is important to improve their pharmacokinetic profiles.
Acknowledgments
We thank Charles River Japan for offering cannulated SD rats.

Authorship Contributions
Participated in research design: Kosaka, Sakai, Endo, Fukuhara, Tsuda-Tsukimoto, and Kume.
Conducted experiments: Kosaka, Sakai, Endo, Fukuhara, Tsuda-Tsukimoto, Ohtsuka, Kino, Tanimoto, Takeba, and Takahashi.
Contributed new reagents or analytic tools: Kosaka and Fukuhara.
Performed data analysis: Kosaka.
Wrote or contributed to the writing of the manuscript: Kosaka and Kume.

References

FIG. 5. Schematic representation of intestinal and hepatic disposition of raloxifene. S, raloxifene; G, glucuronic acid; P-gp, P-glycoprotein.

Address correspondence to: Dr. Keigo Kosaka, DPMP Research Laboratory, Mitsubishi Tanabe Corporation, 2-2-60, Kagawadshi, Toda-shi, Saitama, 335-8505, Japan. E-mail: kosaka.keigo@mt-pharma.co.jp

Mizuno T (2009) Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140–141.